Shots:
- FiberSense has received the CE Marking for its CGM System as a Class IIb medical device, with the company planning to launch in select markets, with initial orders confirmed & first deliveries expected in late 2026
- The company is preparing manufacturing scale-up, logistics, customer support, & market access activities for launch, while advancing its CxM pipeline to evaluate additional sensors targeting ketones, lactate, & cortisol
- The system continuously monitors glucose levels & trends in adults with diabetes using optical sensing tech that measures glucose in tissue fluid beneath the skin. Its sensor & overtape can be worn for ~28 days, while the detector & charger are reusable
Ref: PRnewswire | Image: FiberSense | Press Release
Related News: SurGenTec Wins the US FDA Clearance for ION-L to Treat Degenerative Disc Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
